Anavex Life Sciences Announces Extension of Clinical Study in Alzheimer’s Disease

- October 9th, 2019

The company announced the start of the ATTENTION-AD long-term extension study in patients with early Alzheimer’s disease.

Anavex Life Sciences (NASDAQ:AVXL) has announced the initiation of a long-term extension study for patients with early Alzheimer’s disease being treated with ANAVEX2-73.

As quoted in the press release:

The ATTENTION-AD study (Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004), which is an extension of the Phase 2b/3 ANAVEX®2-73-AD-004 clinical study currently underway, will give AD patients an opportunity to continue their treatment. This study is expected to last two years for patients included in the ANAVEX®2-73-AD-004 study, once they have completed the placebo-controlled 48-week Phase 2b/3 trial.

ATTENTION-AD will be conducted in parallel with the Phase 2b/3 ANAVEX®2-73-AD-004 study.
All patients who participate in the Phase 2b/3 ANAVEX®2-73-AD-004 study will be eligible to participate also in the ATTENTION-AD study under a voluntary open label extension protocol.

“This is an important development as the patients who have completed the main study, ANAVEX2-73-AD-004, are consistently expressing the wish to gain ongoing access to this investigational therapy,” says A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator for both studies.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *